Category Archives: Top News

The CSO of Agios Pharma (NASDAQ: AGIO) is Buying Shares

Today, the CSO of Agios Pharma (NASDAQ: AGIO), Scott Biller, bought shares of AGIO for $81.03K. Following Scott Biller’s last AGIO Buy transaction on June 27, 2017, the stock climbed by 9.3%. Based on Agios Pharma’s latest earnings report for

RBC Capital Sticks to Their Hold Rating for Bank of Montreal

Bank of Montreal (TSX: BMO), the Financial sector company, has received a rating update from a Wall Street analyst on December 6. Analyst Darko Mihelic from RBC Capital rated Bank of Montreal (TSX: BMO) a Hold on on December 6,

Credit Suisse Sticks to Their Buy Rating for Gilead Sciences

Credit Suisse analyst Alethia Young maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) yesterday and set a price target of $82. The company’s shares opened today at $73.20. According to TipRanks.com, Young is a 2-star analyst with an average

Analysts Conflicted on These Healthcare Names: Agios Pharma (NASDAQ: AGIO), Jazz Pharmaceuticals (NASDAQ: JAZZ) and Revance Therapeutics (NASDAQ: RVNC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agios Pharma (NASDAQ: AGIO), Jazz Pharmaceuticals (NASDAQ: JAZZ) and Revance Therapeutics (NASDAQ: RVNC). Agios Pharma (NASDAQ: AGIO) In a report released today, Leah R. Cann

Ambarella Gets a Hold Rating from Oppenheimer

Oppenheimer analyst Andrew Uerkwitz assigned a Hold rating to Ambarella (NASDAQ: AMBA) today. The company’s shares closed yesterday at $54.27. Uerkwitz wrote: “AMBA reported F3Q18 revenues/EPS of $89M/$0.75, slightly ahead of consensus estimates of $89M/$0.67 and our estimates of $90M/$0.69.

Analyst Explains Why They Gilead Sciences Upgrade Their Gilead Sciences Rating

In a report released today, Jason McCarthy from Maxim Group upgraded Gilead Sciences (NASDAQ: GILD) to Buy, with a price target of $94. The company’s shares closed yesterday at $73.67. McCarthy wrote: “We returned from Beijing, China and listened as